Initial Statement of Beneficial Ownership (3)
10 Januar 2022 - 03:16PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
McDermott Michael |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2022
|
3. Issuer Name and Ticker or Trading Symbol
PFIZER INC [PFE]
|
(Last)
(First)
(Middle)
PFIZER INC.-CORP. SECRETARY, 235 EAST 42ND ST. |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Executive Vice President / |
(Street)
NEW YORK, NY 10017
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 66186.0000 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Appreciation Rights | 2/25/2023 (1) | 2/25/2023 (1) | Common Stock | 14178.0000 | $22.8900 | D | |
Stock Appreciation Rights | 2/26/2022 (1) | 2/26/2022 (1) | Common Stock | 12340.0000 | $25.6000 | D | |
Stock Appreciation Rights | 2/23/2022 (2) | 2/23/2022 (2) | Common Stock | 14952.0000 | $27.3400 | D | |
Stock Appreciation Rights | 2/23/2024 (1) | 2/23/2024 (1) | Common Stock | 12412.0000 | $27.3400 | D | |
Stock Appreciation Rights | 2/22/2023 (2) | 2/22/2023 (2) | Common Stock | 13307.0000 | $30.1700 | D | |
Stock Appreciation Rights | 2/22/2025 (1) | 2/22/2025 (1) | Common Stock | 11125.0000 | $30.1700 | D | |
Stock Appreciation Rights | 2/27/2025 (2) | 2/27/2025 (2) | Common Stock | 48419.0000 | $31.3100 | D | |
Stock Appreciation Rights | 2/27/2027 (1) | 2/27/2027 (1) | Common Stock | 41485.0000 | $31.3100 | D | |
Stock Appreciation Rights | 2/25/2026 (2) | 2/25/2026 (2) | Common Stock | 37925.0000 | $33.8200 | D | |
Stock Appreciation Rights | 2/25/2028 (1) | 2/25/2028 (1) | Common Stock | 32769.0000 | $33.8200 | D | |
Stock Appreciation Rights | 2/28/2024 (2) | 2/28/2024 (2) | Common Stock | 18999.0000 | $38.7100 | D | |
Stock Appreciation Rights | 2/28/2026 (1) | 2/28/2026 (1) | Common Stock | 16011.0000 | $38.7100 | D | |
Explanation of Responses: |
(1) | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
(2) | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
McDermott Michael PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK, NY 10017 |
|
| Executive Vice President |
|
Signatures
|
Susan E. Grant, by power of atty., for Michael McDermott | | 1/10/2022 |
**Signature of Reporting Person | Date |
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
Von Mär 2023 bis Mär 2024